MaxCyte inks strategic platform license agreement with TG Therapeutics to advance its autoimmune cell therapeutics ...
MaxCyte, Inc, a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, announced they are entering into a strategic platform …